Newsletters and Deep Dive digital magazine
Regulators and health technology assessment (HTA) bodies are increasingly demanding the patient voice play a central role in drug development – making it riskier for developers to ignore th
In March 2022, Leela Barham argued that, in light o
Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year ann
The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm?
Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs.
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough
What does it take to establish new treatments for rare diseases?